Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma

Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01677468

Enrollment

250

Registered

2012-09-03

Start date

2012-08-31

Completion date

2015-07-31

Last updated

2012-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Transarterial Chemoembolization

Keywords

Hepatocellular carcinoma, Transarterial chemoembolization

Brief summary

The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.

Detailed description

Subjective angiographic chemoembolization endpoints (SACE) levels were developed to standardize the embolic endpoints of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). It determined the antegrade arterial flow and residual tumor blush as follows: I, normal-normal; II, reduced-reduced; III, reduced-none; IV, none-none. SACE level II and III indicates intermediate-levels of embolization, whereas IV indicates overembolization. The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.

Interventions

PROCEDUREIntermediate embolization

TACE with substasis using gelfoam

PROCEDUREComplete embolization

TACE with complete embolization using gelfoam

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* age over 18 * ECOG performance status 0-2 * Hepatocellular carcinoma diagnosed histologically or clinically * Tumor numbers of 5 or less * No history of treatment for hepatocellular carcinoma * Patients with informed consent

Exclusion criteria

* Extrahepatic metastasis * Rupture of hepatocellular carcinoma * Infiltrative hepatocellular carcinoma * Malignancy other than hepatocellular carcinoma

Design outcomes

Primary

Measure	Time frame	Description
Survival rate of the subjects	6 months after TACE	Survival rate of the subjects 6 months after TACE

Secondary

Measure	Time frame	Description
Disease free survival of the subjects	6, 12, 18, and 24 months after TACE	Disease free survival of the subjects, 24 months after TACE
Complication rate of TACE	6, 12, 18, and 24 months after TACE	The incidence of infection, hemorrhage, 24 months after TACE

Countries

South Korea

Contacts

Primary ContactSang Hoon Park, M.D., Ph.D.

dr.sanghoon.park@gmail.com82-2-829-5493

Backup ContactSu Rin Shin, M.D.

dr.goforit@gmail.com82-2-829-5490

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026